Objective. To investigate the prevalence of eight common rheumatic diseases in a large Chinese population.
Introduction
Rheumatic diseases, including RA, SLE and gout, are a significant cause of disability and impaired quality of life. Estimating the burden of these disorders is important for understanding their impact on health care. It has been shown that the prevalence of rheumatic diseases varies with time. For example, epidemiological studies have revealed that the occurrence of RA has declined in recent decades, particularly in the UK, USA and Japan [13] , whereas the prevalence of gout has increased by 80% in the USA [1] .
A number of epidemiological studies of rheumatic diseases in China have been documented [4] . However, the estimation of prevalence in most of these studies was limited by small sample sizes resulting in low statistical power, wide CIs and substantial discrepancies between studies [5, 6] .
This study aimed to address these issues by undertaking the largest population-based survey of the prevalence of common rheumatic diseases conducted in China to date. Data obtained in different regions were compared to assess the current prevalence of common rheumatic diseases in Beijing and to identify changes that have occurred over time.
Materials and methods

Population
In this study, 10 of 42 villages were selected at random from within the Longquan and Yongding areas in the Mentougou district of Beijing. Subjects were selected from the target population of permanent residents (516 years) in these villages. The calculation of sample size was obtained in accordance with a 0.34% expected prevalence of RA, with 0.11% error estimation.
Epidemiological survey
Survey teams composed of at least one rheumatologist and two other trained interviewers conducted a two-stage community-based survey of the incidence of RA, SLE, gout, PsA, SSc, PM/DM, Behç et's disease (BD) and adult-onset Still's disease (AOSD). The first stage involved screening for disease-associated individuals during weekends using a home-administered questionnaire. Subjects not interviewed over weekends on the first occasion were revisited at a later date. Those who refused to participate or were absent on the second visit were excluded as nonresponders. The second stage included a clinical examination of positive responders. Diagnosis was based on the ACR criteria or the criteria used popularly in literature [713] . The screening questionnaire was designed to achieve maximum detection of rheumatic diseases and had been previously validated in a pilot study of diagnosed patients who were identified with 100% sensitivity. This study was approved by the Ethics Committee of Peking University People's Hospital and consent was obtained according to the Declaration of Helsinki at the time of the interview.
Statistical analysis
Data were analysed using SPSS13.0 software (SPSS, Chicago, IL, USA). The differences between multiple age groups and genders were analysed by chi-square test.
Crude prevalence rates were adjusted to a standard Chinese population (nationwide census in 2000). The 95% CIs were calculated using the Poisson distribution. P < 0.05 was considered significant.
Results
The target population consisted of 14 642 subjects, of which 10 556 individuals participated in the study (participation rate 72%). The surveyed population consisted of 5223 (49.48%) males and 5333 (50.52%) females, with a mean age of 45.8 (16.41) years. There were no significant differences in age and gender structure between the target and surveyed populations ( Table 1 ). The response rate for a physical examination among positive responders was 100%.
RA
Of the 10 556 participants, 43 were diagnosed with RA ( Table 2 ). The crude prevalence of RA in the total population was 0.41% (95% CI 0.30%, 0.55%), with 0.11% (95% CI 0.04%, 0.25%) in males and 0.69% (95% CI 0.49%, 0.96%) in females. Thus, the age-adjusted prevalence of RA in the total population was 0.28% (95% CI 0.19%, 0.41%) with 0.08% (95% CI 0.03%, 0.22%) in males and 0.46% (95% CI 0.30%, 0.69%) in females. The adjusted prevalence of RA in females was significantly higher than that in males with a female:male ratio of 6 : 1 (P < 0.01). The prevalence rate increased with age. Significantly higher prevalence rates were observed in middle-aged or older (>46 years) females (P < 0.0001), whereas there was no significant increase in the prevalence rate in males (P = 0.12).
Gout
Gout was diagnosed in 10 individuals, with a crude prevalence of 0.09% (95% CI 0.04%, 0.15%). The mean age of these patients was 58.75 (15.22) years (Table 3) . Thus, the prevalence in males was 0.17% (95% CI 0.08%, 0.33%) and the prevalence in females was 0.01% (95% CI 0%, 0.11%). 
SLE
Three females were diagnosed with SLE. The calculated prevalence was 0.06% (95% CI 0.01%, 0.17%) in females and 0.03% (95% CI 0%, 0.06%) when both sexes were included (Table 3) .
PsA
This study included evaluation of the prevalence of PsA both in the general population and in psoriasis patients. Of the 10 556 individuals, psoriasis was diagnosed in 28 individuals with a prevalence of 0.27% (95% CI 0.17%, 0.36%). The prevalence of PsA was 7.14% (95% CI 0%, 16.68%) in psoriasis patients and 0.02% (95% CI 0%, 0.07%) in the general population (Table 3) .
Other diseases SSc is a rare rheumatic disease that occurs with low prevalence worldwide. A single female (aged 60 years) was diagnosed with SSc in this study. Thus, the prevalence of SSc was 0.01% (95% CI 0%, 0.05%) in the general population. One male (aged 53 years) reported suffering from BD in association with BuddChiari syndrome. As a result, the prevalence of BD was 0.01% (95% CI 0%, 0.05%) in the general population. No cases of PM/DM or AOSD were identified in this study, suggesting that the probable prevalence of these two diseases is <0.01% (Table 3) . identified in Native American populations [37] and very low prevalence in some areas of Africa [38] .
Discussion
RA
Gout
Previous studies have shown that the prevalence of gout varies in different regions of China [3942] . The highest prevalence of gout (11.7%) was identified in Taiwanese aborigines [42] , with a higher prevalence in urban areas (0.67%) compared with that reported in rural areas (0.16%) [43] . Furthermore, low prevalence was reported in the inland city of Taiyuan (0.15%) [6] compared with that in the coastal city of Qingdao (0.36%) [40] . These results suggest the aetiology of gout is influenced by both environmental and genetic factors. In 2002, gout was reported with a prevalence of 0.33% in Shanghai [15], which was higher than that (0.2%) reported in 1992 [5] . Similar increases were revealed by studies conducted in Taiwan and Shantou [41, 43] . An increased prevalence of gout (0.09%) was observed in this study compared with results reported in 1980 in Beijing (0%) [44] , thus providing further evidence of an increased trend in the prevalence of gout over time in China.
The prevalence of gout varied among different populations in this study (Table 5) . A greater number of gout patients have been reported in developed countries such as Japan, UK, Greece, German, USA, New Zealand and Australia compared with China and other developing countries [4555] .
SLE
In this study, SLE was diagnosed in only three cases of a total of 10 556 subjects, giving a prevalence of 0.03%, which is similar to the pooled SLE prevalence of 0.038% in China [5] . Remarkable disparities have been reported in the worldwide distribution of SLE, with a generally lower prevalence in Asian countries (particularly Japan, India and China) compared with North American and some European countries (such as Greece and Sweden) [5666] (Table 6 ).
PsA
The epidemiology of PsA is difficult to determine, largely due to the absence of universally agreed criteria for its diagnosis. Recently the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria was found to have both good sensitivity (91.4%) and specificity (98.7%) [67] . In this study, the CASPAR criteria were used to screen patients for PsA, and a prevalence of 0.02% was identified in the general population, which is similar to results reported previously in several small-scale studies in China [6] . The worldwide prevalence of PsA in the general population is summarized in Table 7 . The incidence of PsA patients in Asian areas (particularly China and Japan) is lower than in North American and European countries [6874] .
Recently the prevalence of PsA in patients with psoriasis was examined [7579] . Theoretically, it provides a more valid overall estimate of the prevalence of PsA. This study is the first large-scale population-based survey in China to investigate the prevalence of PsA in psoriatic patients. It was observed that the proportion of psoriasis patients suffering from PsA (7.14%) in China was lower than that reported previously in the UK (13.8%) [75] , USA (11%) [73] and Germany (19%) [77] , but higher than that in Japan (1%) [78] .
Other diseases
In this study, the prevalence of BD in China was estimated to be 10 per 100 000 individuals. BD is known as Silk Road disease, which is common in the Far East and in countries in the Mediterranean basin, such as Japan, Turkey and Iran [47, 49, 79] . The disease is uncommon in North America and Europe [8085] (Table 8) .
This is the first large-scale population-based survey to demonstrate a prevalence of SSc in China of 10 per 100 000 individuals, slightly lower than the prevalence of 1 patient in 6584 individuals reported by Dai et al. [15] . The worldwide prevalence of SSc ranges from 3.8 to 58 per 100 000 (Table 9 ). The USA [86] , Australia [87] and some southern European countries (such as Greece [50] , Spain [88] , Italy [89] ) have higher frequencies of SSc than Japan [90] and China. Furthermore, the prevalence of SSc in northern European countries (such as England [91] and Iceland [92] ) is relatively low according to previous studies.
The results of this study suggest that the prevalence of AOSD and PM/DM is lower than 10 per 100 000, which is [45] 1.1 in males Vietnam [18] 0.14 Indonesia [46] 1.7 Thailand [22] 0.16 Iran [47] 0.13 Europe UK [48] 1.4 Turkey [49] 0.02 Greece [50] 4.75 Italy [51] 0.46 German [52] 1.4 North America USA [53] 2.7 Mexico [36] 0.3 Cuba [35] 0.38 Oceania New Zealand [54] European subjects 2.9 Maori subjects 6.4 Australia [55] 7.0 in males 0.9 in females [56] 0.0191 Iran [47] 0.04 Pakistan [21] 0.05 Saudi Arabia [57] 0.0193 India [58] 0.0032 Europe France [59] 0.04 Spain [60] 0.03412 Norway [61] 0.0449 UK [62] 0.0407 Turkey [49] 0.059 Greece [50] 0.11 Sweden [63] 0.068 Italy [64] 0.0579 North America USA [65] 0.00580.13 Canada [66] 0.0328 Mexico [36] 0.06 Cuba [35] 0.06 www.rheumatology.oxfordjournals.org similar to the prevalence in Japan (PM/DM 9.92 per 100 000 individuals; AOSD 1.47 per 100 000 females) [96, 97] . Bernatsky et al. [98] reported recently that the prevalence of PM/DM in Quebec, Canada, was 21.5 per 100 000 individuals. In Greece, PM/DM prevalence was 58 per 100 000 individuals [50] . The data show that the prevalence of PM/DM in Europe and North America is relatively higher than in Asia. Furthermore, a survey conducted in Norway reported AOSD prevalence as 6.9 per 100 000 individuals, suggesting the rarity of this disease globally [99] . The worldwide epidemiological studies of PM/DM and AOSD are limited and larger populationbased surveys are required for more accurate information.
In conclusion, our survey provides an estimate of the burden of rheumatic diseases in China. When compared with other countries, the prevalence of RA, SLE and PsA in China is lower than in Europe and North America, but higher than in Japan. China has a low frequency of gout, compared with USA, Europe and Japan. Furthermore, the prevalence of SSc in China is lower than in North America and southern Europe, but higher than Japan and northern Europe. BD is more common in China than in North America and Europe, although the prevalence is similar in Japan. PM/DM and AOSD are rare diseases throughout the world and larger population-based surveys are required for more accurate information regarding the epidemiology of these disorders.
Rheumatology key messages
. RA, SLE, PsA and gout prevalence in China is lower than in the USA and Europe. . BD in China is more common than in the USA and Europe. . SSc prevalence in China is lower than in the USA and southern Europe, but higher than in Japan. 
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